While baseline retention of CD19 intron 2 was already high in B-ALL cell lines (79.6%), IKAROS KD B-ALL cells showed a trend toward higher retention (86.1%; Supplementary Fig. 6D). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.